Antidote and Seqster Join Hands To Advance Patient Identification

Antidote Technologies, a digital health firm that focuses on patient engagement to advance recruitment for clinical trials, and SEQSTER PDM Inc., the leading patient-centric healthcare technology company, declared an agreement to improve patient identification, trial timelines, and enrollment outcomes for Pharma and Life Science organizations with their fully integrated end-to-end solution.

Antidote can better match patients to clinical trials based on a 360-degree view of their medical history, genomic data, and lifestyle factors by utilizing the SEQSTER Operating System. Combining Antidote's best-in-class screening and patient support services with this solution enables faster recruitment of higher-quality patients and a more precise match for potential clinical trials for which they may qualify.

"By integrating SEQSTER’s Operating System with Antidote's precision recruitment capabilities, we are creating a powerful synergy that addresses one of the most pressing challenges in clinical research today: clinical trial recruitment plus engagement. This partnership empowers us to accelerate patient recruitment while providing a comprehensive, real-time view of study participant health data, accelerating the path to medical breakthroughs," stated Ardy Arianpour, CEO & Co-Founder of SEQSTER.

"Our mission at Antidote has always been to connect the right patients with the right trials, striking a balance between advanced technology and a personal touch. Partnering with SEQSTER allows us to enhance our precision recruitment process with unparalleled data integration capabilities, ensuring that we can more effectively identify suitable participants and reduce the time it takes to bring new treatments to market. Together with SEQSTER, we will transform the clinical trial landscape, making it more efficient, inclusive, and patient-centered," explained Samantha Veeck, Co-CEO of Antidote.